Home » News » PLC News » Oncimmune Holdings ANVISA authorisation brings opportunity for EarlyCDT Lung sales in large Brazilian market
Lung testing

Oncimmune Holdings ANVISA authorisation brings opportunity for EarlyCDT Lung sales in large Brazilian market

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced that its distributor in Brazil, Valentech International LLC, has obtained marketing authorisation for the EarlyCDT Lung blood test for the early detection of lung cancer in Brazil from Agência Nacional de Vigilância Sanitária.

Lung cancer is the biggest cancer killer in Brazil; 34,000 people were diagnosed with lung cancer in 2018 and almost 32,000 deaths were reported from the disease in the same year1. Brazil therefore has a high unmet need for new technologies in the earlier detection of lung cancer and presents a significant market opportunity for EarlyCDT Lung.

This marketing authorisation is effective immediately and enables market access for EarlyCDT Lung in one of the largest addressable markets in the world. Oncimmune signed a distribution agreement with Valentech for Brazil and Colombia in 2018.

Dr Adam M Hill, CEO of Oncimmune Holdings said: “Survival rates from lung cancer can be increased significantly with earlier detection of the disease. We are delighted that EarlyCDT Lung can now be made available in this large market, where the need is so great.”

1. https://gco.iarc.fr/today/data/factsheets/populations/76-brazil-fact-sheets.pdf

Join us on our new LinkedIn page

Follow us on LinkedIn